Evaluating Safety and Efficacy of Tranexamic Acid Versus Vaginal Misoprostol in Reducing Intraoperative Blood Loss During Abdominal Myomectomy
Overview
- Phase
- Phase 4
- Intervention
- intravenous tranexamic acid
- Conditions
- Myomectomy
- Sponsor
- Cairo University
- Enrollment
- 162
- Primary Endpoint
- intraoperative blood loss
- Last Updated
- 6 years ago
Overview
Brief Summary
the aim of the present study is to evaluate safety and efficacy of tranexamic acid versus vaginal misoprostol in reducing intraoperative blood loss during abdominal myomectomy
Investigators
Ahmed Samy aly ashour
assistant professor obstetrics and gynecology
Cairo University
Eligibility Criteria
Inclusion Criteria
- •symptomatic fibroids candidate for abdominal myomectomy
Exclusion Criteria
- •myomas candidate for laparoscopic or hysteroscopic myomectomy and allergy or contraindications to misoprostol or tranexamic acid
Arms & Interventions
intravenous tranexamic acid
patients were given a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision plus one vaginal placebo tablet 1 hour before skin incision
Intervention: intravenous tranexamic acid
vaginal misoprostol
patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Intervention: vaginal misoprostol
placebo
patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Intervention: placebo
Outcomes
Primary Outcomes
intraoperative blood loss
Time Frame: one hour
intraoperative blood loss will be estimated during open myomectomy in mL